Business Context and Reporting Period
Tenaya Therapeutics, Inc. (TNYA), a Delaware corporation, filed this Form 8-K on December 11, 2025, to report the entry into a material definitive agreement. The company is an emerging growth company focused on developing therapies for rare diseases.
Key Financial Metrics and Transaction Details
This filing details a firm commitment underwritten public offering rather than historical financial performance. Key transaction metrics include:
- Offering Size: 50,000,000 Units.
- Public Offering Price: $1.20 per Unit.
- Unit Composition: One share of Common Stock and one Warrant to purchase one share of Common Stock.
- Warrant Terms: Exercise price of $1.50 per share; exercisable for five years from issuance.
- Underwriting Price: $1.128 per Unit (net to Company before expenses).
- Expected Gross Proceeds: Approximately $60 million.
- Expected Closing Date: December 15, 2025.
The filing does not provide current revenue, profit, cash flow, or debt figures; these are not applicable to this specific event-driven report.
Material Changes and Lock-Up Provisions
The primary material change is the dilution of existing shareholders due to the issuance of new shares and warrants. Additionally, the Company, its officers, directors, and certain other holders have agreed to a 60-day lock-up period following the Underwriting Agreement date, during which they cannot offer, sell, or transfer shares without the Representatives' written consent.
Outlook, Risks, and Contingencies
The Offering is subject to customary closing conditions. The filing includes forward-looking statements regarding the size, terms, timing, and completion of the Offering, noting that actual results may differ due to market conditions or failure to satisfy closing conditions. The Company disclaims any obligation to update these statements. Further risk factors are referenced in the Company's Form 10-Q filed on November 10, 2025.
Investor Verification Checklist
- Confirm the final closing of the Offering on or around December 15, 2025.
- Verify the actual net proceeds after deducting underwriting discounts and offering expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) and Form of Warrant (Exhibit 4.1) for specific covenants and adjustment mechanisms.
- Assess the impact of the 60-day lock-up period on secondary market liquidity.
- Consult the November 10, 2025 Form 10-Q for the most recent liquidity position and risk factors.